|Home||» Products||» Neurological Disorders Drugs||» Amantadine hydrochloride|
- Minimum Order Quantity
AMANTREL Capsules are indicated in the treatment of idiopathic Parkinson’s disease (paralysis agitans), post-encephalitic Parkinsonism and symptomatic Parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop Parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson’s disease, AMANTREL Capsules are less effective than levodopa (-)-3-(3,4dihydroxyphenyl)-L-alanine, and their efficacy in comparison with the anticholinergic anti-Parkinson drugs has not yet been established.
Drug-Induced Extrapyramidal Reactions
AMANTREL Capsules are indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with AMANTREL Capsules when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic anti-Parkinson drugs.
Influenza A Prophylaxis
AMANTREL Capsules are indicated for chemoprophylaxis against the signs and symptoms of influenza A virus infection. Because AMANTREL Capsules do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza A outbreak, AMANTREL Capsules prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response.
Influenza A Treatment
Amantadine is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with AMANTREL Capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients.
- Main Export Market(s)
- Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia